Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy
O’Neill, Brian T. , Penniman, Christie M., Krumpoch, Megan, Beltran, Pablo A. Suarez, Klaus, Katherine A. , Poro, Kennedy, Pan, Hui , Klaus, Katherine, Kahn, C Ronald , Bhardwaj, Gourav , Li, Mengyao , Pan, Hui , Dreyfuss, Jonathan M. , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | December 6, 2018 | Volume: 68 | Issue: 3 | Pages: 556-570

10.2337/db18-0416 | PMID 30523026 Get It

Insulin deficiency and uncontrolled diabetes lead to a catabolic state with decreased muscle strength, contributing to disease-related morbidity. FoxO transcription factors are suppressed by insulin and thus are key mediators of insulin action. To study their role in diabetic muscle wasting, we created mice with muscle-specific triple knockout of FoxO1/3/4 and induced diabetes in these M-FoxO-TKO mice with streptozotocin (STZ). Muscle mass and myofiber area were decreased 20–30% in STZ-Diabetes mice due to increased ubiquitin-proteasome degradation and autophagy alterations, characterized by increased LC3-containing vesicles, and elevated levels of phosphorylated ULK1 and LC3-II. Both the muscle loss and markers of increased degradation/autophagy were completely prevented in STZ FoxO-TKO mice. Transcriptomic analyses revealed FoxO-dependent increases in ubiquitin-mediated proteolysis pathways in STZ-Diabetes, including regulation of Fbxo32 (Atrogin1), Trim63 (MuRF1), Bnip3L, and Gabarapl. These same genes were increased 1.4- to 3.3-fold in muscle from humans with type 1 diabetes after short-term insulin deprivation. Thus, FoxO-regulated genes play a rate-limiting role in increased protein degradation and muscle atrophy in insulin-deficient diabetes.
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, Deli , Fritz, Andrew J. , Gordon, Jonathan A. R., Tracy, Kirsten M. , Frietze, Seth , Carr, Frances E. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Zaidi, Sayyed K. , Lian, Jane B. , Stein, Janet L. , Tracy, Kirsten M , van Wijnen, Andre J , Stein, Gary S , Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | December 5, 2018 | Volume: 234 | Issue: 6 | Pages: 8597-8609

10.1002/jcp.27841 | PMID 30515788 Get It

AbstractThe RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context‐dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial‐to‐mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context‐dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.
Amyloid- and tau-PET imaging in a familial prion kindred
Townley, Ryan , Graff‐Radford, Jonathan , Botha, Hugo , Petersen, Ronald C. , Jack, Clifford R. , Lowe, Val J. , Townley, Ryan A, Jack, Clifford R , Botha, Hugo , Jones, David T. , Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Neurology Genetics | December 4, 2018 | Volume: 4 | Issue: 6 | Pages: No page available

10.1212/nxg.0000000000000290 | PMID 30584595 Get It

The King-Devick test in mixed martial arts: the immediate consequences of knock-outs, technical knock-outs, and chokes on brain functions
Hubbard, Ryan , Stringer, Gene, Peterson, Ken, Carneiro, Mario Roberto Filho Vaz, Savica, Rodolfo , Finnoff, Jonathan T. , Stringer, Gene C.

Mayo Clinic

Brain Injury | December 3, 2018 | Volume: 33 | Issue: 3 | Pages: 349-354

10.1080/02699052.2018.1553068 | PMID 30507317 Get It

Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Olmedo, Wilman, Villablanca, Pedro , Sanina, Cristina , Weinreich, Michael , Brevik, Jeannine, Avendaño, Ricardo , Bravo, Claudio , Babaev, Anvar, Attubato, Michael , Hernandez-Suarez, DF, Cox‐Alomar, Pedro, Pyo, Robert, Krishnan, Prakash , Wiley, José , Villablanca, Pedro A , Avendano, Ricardo , Ramakrishna, Harish , Hernandez-Suarez, D F , Walker, Jonathan R. , Romero, Jorge E.

Mayo Clinic

Vascular | December 1, 2018 | Volume: 27 | Issue: 1 | Pages: 78-89

10.1177/1708538118807522 | PMID 30501582 Get It

Background Bivalirudin may be an effective alternative anticoagulant to heparin for use in percutaneous peripheral interventions. We aimed to compare the safety and efficacy of bivalirudin versus heparin as the procedural anticoagulant agent in patients undergoing percutaneous peripheral intervention. Methods For this meta-analysis and systematic review, we conducted a search in PubMed, Medline, Embase, and Cochrane for all the clinical studies in which bivalirudin was compared to heparin as the procedural anticoagulant in percutaneous peripheral interventions. Outcomes studied included all-cause mortality, all-bleeding, major and minor bleeding, and access site complications. Results Eleven studies were included in the analysis, totaling 20,137 patients. There was a significant difference favoring bivalirudin over heparin for all-cause mortality (risk ratio 0.58, 95% CI 0.39–0.87), all-bleeding (risk ratio 0.62, 95% CI 0.50–0.78), major bleeding (risk ratio 0.61, 95% CI 0.39–0.96), minor bleeding (risk ratio 0.66, 95% CI 0.47–0.92), and access site complications (risk ratio 0.66, 95% CI 0.51–0.84). There was no significant difference in peri-procedural need for blood transfusions (risk ratio 0.79, 95% CI 0.57–1.08), myocardial infarction (risk ratio 0.87, 95% CI 0.59–1.28), stroke (risk ratio 0.77, 95% CI 0.59–1.01), intracranial bleeding (risk ratio 0.77, 95% CI 0.29–2.02), or amputations (OR 0.75, 95% CI 0.53–1.05). Conclusion Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results.
A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Jensen, Allan , Wiensch, Ashley , Lee, Alice W. , Ness, Roberta B., Salvatore, Maxwell , Tworoger, Shelley S. , Whittemore, Alice S. , Sieh, Weiva , Goode, Ellen L. , Goodman, Marc T. , Chenevix‐Trench, Georgia , Rossing, Mary Anne, Webb, Penelope M. , Terry, Kathryn L. , Fortner, Renée T. , Menon, Usha , Gayther, Simon A. , Wu, Anna H. , Song, Honglin , Brooks‐Wilson, Angela , Thompson, Pamela J., Chang‐Claude, Jenny , Schildkraut, Joellen M. , Le, Nhu D. , Wentzensen, Nico, Trabert, Britton , Høgdall, Estrid , Huntsman, David G. , Pike, Malcolm C. , Pearce, Celeste Leigh , Salvatore, Maxwell , Anton-Culver, Hoda , Goode, Ellen L , Fortner, Renée T , Wu, Anna H. , Cramer, Daniel W , Modugno, Francesmary , Trabert, B , Pike, Malcolm C , Pearce, Celeste Leigh , Tworoger, Shelley S , Webb, Penelope M , Jensen, Allan , Menon, Usha , Brooks-Wilson, Angela R , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Goodman, Marc T , Kim, Sehee , Wang, Miao , Tyrer, Jonathan P. , Liu, Gang , Anton‐Culver, Hoda , Olson, Sara H. , Berchuck, Andrew , Doherty, Jennifer A. , Giles, Graham G. , Ziogas, Argyrios , Bandera, Elisa V. , Cook, Linda S. , Cramer, Daniel W. , Milne, Roger L. , Winham, Stacey J. , Kjær, Susanne K. , Modugno, Francesmary , Harris, Holly R. , Pharoah, Paul D.P. , Mukherjee, Bhramar

Mayo Clinic

International Journal of Cancer | November 30, 2018 | Volume: 144 | Issue: 9 | Pages: 2192-2205

10.1002/ijc.32029 | PMID 30499236 Get It

As a follow‐up to genome‐wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well‐known ovarian cancer risk factors and their interactions with 28 genome‐wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case–control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10−4). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46–0.60) compared to 0.71 (95%CI = 0.66–0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1–5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene–environment analysis in ovarian cancer.
Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus
Buckley, Melissa A., Woods, Nicholas T. , Mendoza-Fandiño, Gustavo, Lawrenson, Kate , Hazelett, Dennis J. , Najafabadi, Hamed S. , Gjyshi, Anxhela, Carvalho, Renato S. , Lyra, Paulo C. , Shen, Howard C., Yang, Ally , Earp, Madalene A. , Yoder, Sean J., Chenevix‐Trench, Georgia , Ramus, Susan J. , Phelan, Catherine M., Coetzee, Gerhard A., Hughes, Timothy R. , Sellers, Thomas A. , Goode, Ellen L. , Gayther, Simon A. , Monteiro, Álvaro N.A. , Lu, Karen H. , Goodman, Marc T. , Lissowska, Jolanta , Jakubowska, Anna , Dörk, Thilo , Matsuo, Keitaro , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Ekici, Arif B. , Chen, Y. Ann , Eccles, Diana , Teo, Soo‐Hwang , Hein, Alexander , Hillemanns, Peter , Lambrechts, Diether , Jensen, Allan , Brooks‐Wilson, Angela , Sieh, Weiva , Dansonka‐Mieszkowska, Agnieszka , Liang, Dong , Woo, Yin Ling , McNeish, Iain A. , Lambrechts, Diether , Lawrenson, Kate , Hazelett, Dennis J , Najafabadi, Hamed S , Coetzee, Simon G , Ramus, Susan J , Noushmehr, Houtan , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Lissowska, Jolanta , Brooks-Wilson, Angela R , Matsuo, Keitaro , Jakubowska, Anna , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Chenevix-Trench, Georgia , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Yoder, Sean , Risch, Harvey A. , Noushmehr, Houtan , Pharoah, Paul D.P. , Morais Lyra, Paulo Cilas

Mayo Clinic

Cancer Research | November 28, 2018 | Volume: 79 | Issue: 3 | Pages: 467-481

10.1158/0008-5472.can-17-3864 | PMID 30487138 Get It

Abstract Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and assess underlying biological mechanisms at chromosome 9p22.2, the first and most statistically significant associated locus for ovarian cancer susceptibility. Three transcriptional regulatory elements with allele-specific effects and a scaffold/matrix attachment region were characterized and, through physical DNA interactions, BNC2 was established as the most likely target gene. We determined the consensus binding sequence for BNC2 in vitro, verified its enrichment in BNC2 ChIP-seq regions, and validated a set of its downstream target genes. Fine-mapping by dense regional genotyping in over 15,000 ovarian cancer cases and 30,000 controls identified SNPs in the scaffold/matrix attachment region as among the most likely causal variants. This study reveals a comprehensive regulatory landscape at 9p22.2 and proposes a likely mechanism of susceptibility to ovarian cancer. Significance: Mapping the 9p22.2 ovarian cancer risk locus identifies BNC2 as an ovarian cancer risk gene. See related commentary by Choi and Brown, p. 439
2289. Accuracy of a Rapid Multiplex PCR Plus a Chromogenic Phenotypic Test Algorithm for the Detection of ESBL and Carbapenemase-Producing Gram Negatives Directly From Blood Cultures
Hon, Pei-Yun, Wee, Sharon , Chia, Jonathan W. Z., Mendis, Shehara M, Izharrudin, Ezlyn, Lin, Ray J H, Chia, Po Ying , Sim, Rees Chin Swee, Teng, Christine B. , Banerjee, Ritu , De, Partha Pratim, Vasoo, Shawn , Lin, Ray J H, Chen, Mark , Chow, Angela , Yoong, Joanne , Lye, David Chien , Tambyah, Paul Anantharajah , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S678-S678

10.1093/ofid/ofy210.1942 Get It

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Qu, Xiaoyu , Braziel, Rita M., Passerini, Verena , Leonard, John P. , Smith, Sonali M. , Kridel, Robert , Press, Oliver W. , Weigert, Oliver , Friedberg, Jonathan W. , Fang, Min , Press, Oliver , Li, Hongli , Rimsza, Lisa M. , Hsi, Eric D. , Kridel, Robert , LeBlanc, Michael

Mayo Clinic

Blood | November 19, 2018 | Volume: 133 | Issue: 1 | Pages: 81-93

10.1182/blood-2018-07-865428 | PMID 30446494 Get It

Abstract Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs/cnLOH were identified: whereas early progression was correlated with 2p gain (P = .007; odds ratio [OR] = 2.55 [1.29, 5.03]) and 2p cnLOH (P = .005; OR = 10.9 [2.08, 57.2]), 2p gain specifically encompassing VRK2 and FANCL predicted PFS (P = .01; hazard ratio = 1.80 [1.14, 2.68]) as well as OS (P = .005; 2.40 [1.30, 4.40]); CDKN2A/B (9p) deletion correlated with worse PFS (P = .004, 3.50 [1.51, 8.28]); whereas CREBBP (16p) (P < .001; 6.70 [2.52, 17.58]) and TP53 (17p) (P < .001; 3.90 [1.85, 8.31]) deletion predicted worse OS. An independent cohort from the m7-FLIPI study was explored, and the prognostic significance of aberration count, and TP53 and CDKN2A/B deletion were further validated. In conclusion, assessing genomic aberrations at FL diagnosis with CGAT improves risk stratification independent of known clinical parameters, and provides a framework for development of future rational targeted therapies.
Enrichment sampling for a multi-site patient survey using electronic health records and census data
Mercaldo, Nathaniel D. , Brothers, Kyle B. , Connolly, John J. , Horowitz, Carol R. , Jarvik, Gail P. , Kitchner, Terrie, Li, Rongling, McCarty, Catherine A. , McManus, Valerie, Myers, Melanie F. , Pankratz, Joshua J., Shrubsole, Martha J. , Smith, Maureen E. , Stallings, Sarah , Williams, Janet L. , Schildcrout, Jonathan S. , McCormick, Jennifer B, Mercaldo, Nathaniel D , Myers, Melanie F , Shrubsole, Martha J , Schildcrout, Jonathan S , Jarvik, Gail P , Connolly, John J , Carrell, David , Clayton, Ellen Wright , Holm, Ingrid A. , McCormick, Jennifer Blair

Mayo Clinic

Journal of the American Medical Informatics Association | November 16, 2018 | Volume: 26 | Issue: 3 | Pages: 219-227

10.1093/jamia/ocy164 | PMID 30590688 Get It

Abstract Objective We describe a stratified sampling design that combines electronic health records (EHRs) and United States Census (USC) data to construct the sampling frame and an algorithm to enrich the sample with individuals belonging to rarer strata. Materials and Methods This design was developed for a multi-site survey that sought to examine patient concerns about and barriers to participating in research studies, especially among under-studied populations (eg, minorities, low educational attainment). We defined sampling strata by cross-tabulating several socio-demographic variables obtained from EHR and augmented with census-block-level USC data. We oversampled rarer and historically underrepresented subpopulations. Results The sampling strategy, which included USC-supplemented EHR data, led to a far more diverse sample than would have been expected under random sampling (eg, 3-, 8-, 7-, and 12-fold increase in African Americans, Asians, Hispanics and those with less than a high school degree, respectively). We observed that our EHR data tended to misclassify minority races more often than majority races, and that non-majority races, Latino ethnicity, younger adult age, lower education, and urban/suburban living were each associated with lower response rates to the mailed surveys. Discussion We observed substantial enrichment from rarer subpopulations. The magnitude of the enrichment depends on the accuracy of the variables that define the sampling strata and the overall response rate. Conclusion EHR and USC data may be used to define sampling strata that in turn may be used to enrich the final study sample. This design may be of particular interest for studies of rarer and understudied populations.